Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 4,840,000 shares, a decline of 9.4% from the March 31st total of 5,340,000 shares. Based on an average daily volume of 642,000 shares, the […]
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $9.31 and traded as low as $3.90. Cara Therapeutics shares last traded at $3.93, with a volume of 511,942 shares changing hands. Analyst […]
Intrepid Financial Planning Group LLC decreased its holdings in Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) by 20.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,500 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the period. Intrepid […]
Pinnacle Associates Ltd. decreased its stake in Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) by 2.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 687,885 shares of the biopharmaceutical company’s stock after selling 17,482 shares during the quarter. Pinnacle Associates Ltd. owned approximately 1.28% […]